Introduction {#s1}
============

Facilitated by globalization and climate change, arthropod-borne viruses (arboviruses) increasingly pose a threat to human and animal health ([@bib21]). Although for some arboviruses vaccines are available that can be used to prevent or control outbreaks, for the vast majority of emerging arboviruses no countermeasures are available. Rift Valley fever virus (RVFV), a phlebovirus within the order *Bunyavirales*, is prioritized by the World Health Organization (WHO) as being likely to cause major epidemics for which no, or insufficient countermeasures exist. RVFV is currently confined to the African continent, the Arabian Peninsula and several islands off the coast of Southern Africa, where it causes recurrent outbreaks ([@bib9]). The world-wide distribution of competent mosquito vectors and susceptible animals underscores the risk for emergence in currently unaffected areas. In endemic areas, RVFV causes major epizootics among livestock, characterized by abortion storms and large-scale mortality among newborn ruminants. Importantly, the virus also infects humans, either through direct contact with infected animal tissues or via the bites of infected mosquitoes ([@bib30]). Infected individuals generally present with mild to severe flu-like symptoms, however a minority of patients may develop encephalitis or hemorrhagic fever.

In addition to members of the family *Phenuiviridae*, like RVFV, members of the family *Peribunyaviridae*, genus *Orthobunyavirus,* may also cause severe disease in humans and animals. In 2011, the incursion of Schmallenberg virus (SBV) in Europe demonstrated that orthobunyaviruses are capable of spreading very efficiently across new territories. SBV infections are associated with fever and reduced milk production in cows and severe malformations in offspring of both large and small ruminants ([@bib32]; [@bib58]). SBV is categorized as a biosafety level-2 pathogen and is not pathogenic to humans, facilitating its use as a model of zoonotic orthobunyaviruses that require a higher level of containment ([@bib19]; [@bib61]; [@bib60]).

At the moment, no effective antiviral therapy is available to treat bunyavirus infections in humans. Patients essentially rely on supportive care. Some promising pre-clinical and clinical data have been obtained with small molecules, mainly nucleoside analogues, that interfere with viral replication ([@bib22]). Recent X-ray crystallography and cryo-electron microscopy/tomography data have provided novel insights into the bunyavirus glycoprotein architecture that may facilitate the development of bunyavirus antibody therapies in the future ([@bib72]; [@bib31]; [@bib24]). After vaccines, antibody therapies are considered the most effective tools to fight (re)emerging life-threatening viral infections ([@bib38]).

A very wide range of approaches are currently used to isolate natural antibodies and to design synthetic constructs. Most of these efforts are based on neutralizing antibodies or antibody fragments of murine or human origin. In general, these molecules consist of heavy and light polypeptide chains linked by disulphide bonds. Interestingly, in only a few species such as camelids and nurse sharks, heavy chain-only antibodies (HCAbs) are found, of which the antigen binding domain can be expressed as a single-domain antibody (sdAb) ([@bib4]). Camelid derived sdAbs, known as VHHs, are increasingly used as tools in medicine, including virus neutralization ([@bib71]; [@bib12]). VHHs are intrinsically highly soluble molecules and due to their distinctive structure with extended antigen-binding CDR3 region and overall small size, some are able to target unique (cryptic) antigenic sites not accessible to conventional antibodies ([@bib52]). VHHs with nanomolar or even picomolar affinity targeting a broad spectrum of antigens have been described ([@bib38]; [@bib4]). The single-domain nature additionally allows easy genetic manipulation and favors efficient expression in various heterologous systems including microorganisms ([@bib29]; [@bib48]).

So far, VHHs have been explored as tools for a wide range of applications including their use as therapeutic agents ([@bib71]; [@bib29]; [@bib5]; [@bib57]; [@bib20]). With respect to virus neutralization, a multimeric VHH has shown great promise in counteracting severe pulmonary disease in infants caused by respiratory syncytial virus (RSV) ([@bib14]). The therapeutic potency of complexes consisting of multimers of the same VHH (multivalent) or combinations of VHHs targeting different antigenic sites (multispecific) is explained by their improved avidity, selectivity and kinetics compared to individual VHHs ([@bib35]). Although techniques to use VHHs as building blocks to generate multifunctional molecules are well established, selection of the optimal VHH combination and optimal VHH formats is still challenging ([@bib36]).

Recently, the discovery of \'bacterial superglues\' has enabled the creation of unique protein architectures. The superglues are comprised of a bacterially-derived peptide and a small protein able to form unbreakable isopeptide bonds ([@bib62]). The first bacterial superglue was developed by splitting the immunoglobulin-like collagen adhesion domain (CnaB2) of the fibronectin binding protein (FbaB) of *Streptococcus pyogenes* ([@bib73]) into a peptide and a protein fragment referred to as SpyTag and SpyCatcher. When the two peptides meet, an amide bond is formed which is highly specific and irreversible. Covalent bond formation occurs within minutes upon mixing and is highly robust under various conditions ([@bib73]). The potency of SpyTag:SpyCatcher has already found applications in various disciplines and triggered the search for various additional protein and peptide partners ([@bib63]; [@bib55]).

Here, we selected and characterized RVFV and SBV-specific VHHs targeting receptor binding glycoprotein domains, and used bacterial superglues to create virus neutralizing VHH complexes that reduced and prevented morbidity and mortality in mouse models. Selected RVFV VHHs were subsequently reformatted into human Fc-based bispecific chimeric HCAbs that showed protection in pre- and post-exposure treatments.

Results {#s2}
=======

Selection of RVFV and SBV-specific VHHs {#s2-1}
---------------------------------------

To obtain a source of RVFV and SBV-specific VHHs with potential neutralizing activity for the respective viruses, llamas were inoculated with the live-attenuated RVFV vaccine strain Clone 13, RVFV virus-like particles (VLPs) or SBV NL-F6 ([Figure 1A](#fig1){ref-type="fig"}). All inoculated animals responded well with virus-specific neutralizing antibodies in serum above a 50% neutralizing titer of 500 ([Figure 1B](#fig1){ref-type="fig"}; [@bib70]; [@bib49]). The B-cell-derived VHH phagemid libraries contained \>10^7^ unique clones per animal.

![Selection and expression of RVFV and SBV-specific VHHs.\
(**A**) Illustration of the llama immunization strategy to obtain a source for RVFV and SBV-specific VHHs. (**B**) RVFV and SBV-specific virus neutralizing responses in llama sera determined by virus neutralization test (VNT) before (pre) and post immunization. Neutralizing antibody titers were measured by endpoint titration and calculated as 50% neutralization. (**C**) Schematic presentation of the VHH library construction and phage display selections. Blood lymphocyte RNA was used as a template for VHH-specific PCRs and purified fragments were cloned into phagemids generating a phagemid library. Following phagemid transduction, the purified phage library was screened for antigen-specific phages. (**D**) Summarizing table of the VHH clone selection showing the number (\#) of unique clones identified and the number of CDR groups per antigen. (**E**) SDS-PAGE of yeast-expressed RVFV and SBV-specific VHHs. SB10 was shown to be partly N-glycosylated as confirmed by PNGase F based deglycosylation (lane SB10\*). (**F**) RVFV-Gn~ecto~ and (**G**) SBV-Gc~head~-specific indirect ELISAs. The color coding of the individual VHHs is based on the outcome of the competition ELISA result as presented in [Figure 2A and B](#fig2){ref-type="fig"}.](elife-52716-fig1){#fig1}

RVFV and SBV-specific VHHs were isolated from VHH phage display libraries by pannings with the RVFV Gn ectodomain (RVFV-Gn~ecto~) ([@bib11]) or the SBV Gc head domain (SBV-Gc~head~) ([Figure 1C](#fig1){ref-type="fig"}; [@bib31]), previously described as the Gc *N*-terminal subdomain of 234 amino acids (Gc Amino) ([@bib69]). Both RVFV-Gn~ecto~ and SBV-Gc~head~ are considered to be the main targets of neutralizing antibodies against the respective viruses ([@bib31]; [@bib69]; [@bib53]; [@bib40]; [@bib42]). Supernatants of induced clones were screened for RVFV-Gn~ecto~ and SBV-Gc~head~ specificity by indirect ELISA and immunoperoxidase monolayer assay (IPMA). In total 62 unique RVFV-Gn~ecto~-specific clones that grouped into 16 CDR groups (15 CDR3 groups) and 15 unique SBV-Gc~head~-specific clones that grouped into 6 CDR3 groups were identified ([Figure 1D](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). One representative VHH per CDR group was subsequently produced in yeast ([Figure 1E](#fig1){ref-type="fig"}). All yeast expressed VHHs were confirmed to recognize soluble RVFV-Gn~ecto~, or SBV-Gc~head~ by ELISA ([Figure 1F,G](#fig1){ref-type="fig"}) and/or were found to bind to fixed viral antigen in infected cells ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).

RVFV and SBV VHHs recognize distinct antigenic sites {#s2-2}
----------------------------------------------------

To determine the number of antigenic sites targeted by the different VHHs, RVFV-Gn~ecto~ and SBV-Gc~head~-specific competition ELISAs were performed. The RVFV VHH panel (N = 16) was shown to target three independent antigenic sites within RVFV-Gn~ecto~, referred to as the red, blue and yellow antigenic sites ([Figure 2A](#fig2){ref-type="fig"}). When compared to the VHHs of the blue and the yellow antigenic sites, all of the VHHs of the red antigenic site did not show typical sigmoidal curves, suggesting markedly reduced avidity for monomeric Gn~ecto~ ([Figure 1F](#fig1){ref-type="fig"}). The SBV-specific VHHs showed a more complex pattern of competition ([Figure 2B](#fig2){ref-type="fig"}). SB10 (beige) clearly targets an antigenic site that does not overlap with the sites targeted by the other five VHHs. SB12 and SB13 (orange) recognize the same antigenic site that does not overlap with the site targeted by SB11 (green). However, SB9 and SB14 (violet) show reciprocal competition with each other and SB9 competes (reciprocally) with SB11. SB14 shows non-reciprocal competition with SB12 and SB13, which strongly suggests that the epitopes of SB9, SB11, SB12, SB13 and SB14 are all in very close proximity ([Figure 2B](#fig2){ref-type="fig"}).

![Characterization of VHH binding sites.\
(**A**) RVFV and (**B**) SBV-specific VHHs and antibodies were tested in competition ELISA using RVFV-Gn~ecto~ and SBV-Gc~head~ as antigens. Competition is expressed as percentage of blocking. A percentage above 50% is considered efficient blocking and strongly suggests that the test VHH binds at an overlapping site in the antigen as the blocking VHH. For SBV, competition was additionally assessed for the 1C11 and 4B6 mouse mAbs ([@bib31]). The RVFV-specific VHHs clustered into three groups each targeting a different antigenic site in RVFV-Gn~ecto~ and the SBV VHH panel was shown to target 4 different antigenic sites in SBV-Gc~head~ (of which the green, violet and orange sites are shown to be partly overlapping). Since SB11 and SB14 showed efficient competition (although non-reciprocal) with 1C11, the green, violet and orange antigenic sites are expected to be located at the apical end of the SBV-Gc~head~ domain. (**C**) SDS-PAGE of the baculovirus produced head, A, β-ribbon and B subdomains of RVFV-Gn~ecto~. The lowest band in the subdomain A lane is expected to be the result of proteolytic cleavage. (**D**) RVFV-Gn~ecto~ subdomain-based VHH ELISAs. Wells were coated with the indicated subdomains and VHH binding was assessed with a HRP-conjugated goat anti-llama IgG. (**E**) SB10 escape mutant selection. Briefly, wildtype SBV was sequentially passaged in the absence or presence of SB10. Following passage 6, the Gc~head~ coding region was sequenced and SB10 neutralization was quantitatively assessed. (**F**) Model of a pentameric RVFV spike. The RVFV Gn/Gc heterodimer within a penton (PDB: 6F9F, [@bib24]) is color-coded by domains. The Gn head domain is outlined in black. Arrows indicate approximate positions of the two mapped antigenic sites. (**G**) Model of a trimeric SBV spike based on the monomeric SBV crystal structure (PDB: 6H3S, [@bib31]) and the trimeric BUNV cryo-ET map (EMDB: EMD-2352, [@bib8]). A protomer is color-coded by domains and the Gc head domain is outlined in black. The two N-glycans are labelled with the positions of their respective asparagine residues and the position of the SB10 escape mutation is indicated with a star. Arrows indicate approximate positions of the antigenic sites. Antigenic sites for which evidence is inconclusive are indicated with question marks (green and beige sites).](elife-52716-fig2){#fig2}

Mapping of the RVFV VHHs to the RVFV-Gn head domain {#s2-3}
---------------------------------------------------

The N-terminal 154--469 amino acids of RVFV-Gn~ecto~, now known as the RVFV-Gn head domain, was recently crystallized and shown to comprise three subdomains; subdomain A (or I), β ribbon domain (II) and domain B (III) ([@bib72]; [@bib24]). To assess whether the VHHs target a specific subdomain, the head domain as well as the individual subdomains were expressed using the baculovirus expression system. The subdomains were expressed successfully ([Figure 2C](#fig2){ref-type="fig"}) and binding to the RVFV VHHs was assessed by indirect ELISA ([Figure 2D](#fig2){ref-type="fig"}). The results show that the yellow antigenic site, which is targeted by RV104, RV136 and RV148, is located on subdomain B and that the blue antigenic site, recognized by RV107 and RV115, is primarily located on the β-ribbon domain. The red antigenic site could not be mapped to a specific subdomain, suggesting that this site is present at a subdomain interface. Gn, as part of the Gn/Gc heterodimer, is organized similarly in both hexamers and pentamers on the RVFV particle, of which Gn is most exposed to the immune system. We mapped the antigenic sites to the previously proposed Gn structure within the pentameric capsomer density ([Figure 2F](#fig2){ref-type="fig"}).

Mapping of the SBV VHHs on the SBV-Gc head domain {#s2-4}
-------------------------------------------------

The SBV-Gc head domain is the most exposed feature on the virus envelope, and based on homology with other orthobunyaviruses, it is believed to reversibly form homotrimers among neighboring Gc molecules ([@bib31]). Crystal structures of the head domain in complex with two neutralizing murine mAbs, referred to as 1C11 and 4B6, have recently shown that 1C11 binds to the apical end of the head domain, near the N686 glycosylation site, and that 4B6 binds to the opposite, basal end of the head domain, near its connection to the stalk ([@bib31]). Binding of either antibody is sterically incompatible with head domain trimerization, suggesting that neutralization may at least be partially mediated by destabilization of the spike's quaternary structure ([@bib31]). Competition ELISAs with 1C11 and 4B6 and our SBV VHH panel suggests that SB11 and SB14 target the same antigenic site as 1C11 at the apical end of the domain, whereas no competition was observed with 4B6 ([Figure 2B](#fig2){ref-type="fig"}). For SB10, of which the antigenic site is independent from the others, we generated an escape mutant carrying the single point mutation Y541C located directly at the head domain's contact area with the stalk ([Figure 2E,G](#fig2){ref-type="fig"}). This site likely acts as a hinge allowing the head domain to adopt different orientations relative to the virion surface ([@bib31]), and antibody binding is thus expected to restrain the local mobility of the spike.

Multimeric VHH complexes show superior neutralization activity {#s2-5}
--------------------------------------------------------------

The virus neutralizing activity of selected VHHs, representative for each antigenic site, was evaluated with RVFV and SBV-specific virus neutralization tests (VNTs). At nM range concentrations, no neutralization was observed for any of the monovalent VHHs ([Figure 3](#fig3){ref-type="fig"}; left panel of the figure and diagonal set of bars). Since synergistic effects have been reported for combinations of monoclonal antibodies in bunyavirus neutralization ([@bib6]), we subsequently tested mixtures of VHHs. Combining two VHHs in the VNT assays resulted in moderate neutralization for some SBV VHH combinations (ND~50~ around 200 nM) whereas still no neutralization was observed for RVFV VHH mixtures ([Figure 3](#fig3){ref-type="fig"}; left part of the figure with double colored bars). We therefore assessed whether multimerization supports efficient neutralization. In order to facilitate the screening of a large set of bivalent and bispecific complexes including various linker lengths and without the need to construct a lot of expression plasmids, we used the advantageous properties of bacterial superglue. VHHs were expressed with Spy- and SnoopTags and flexible scaffolds consisting of one, two or three elastin-like protein (ELP) domains were expressed with Spy- and SnoopCatcher domains. By simply mixing the tagged VHH versions with the Catcher containing ELP scaffolds, bivalent and bispecific complexes were constructed ([Figure 4](#fig4){ref-type="fig"}). The VNT assays subsequently revealed that several multimeric complexes very efficiently neutralized with ND~50~ \<10 nM ([Figure 3](#fig3){ref-type="fig"}; middle and right panels). For RVFV, targeting of two distinct antigenic sites seemed a prerequisite to enable efficient neutralization ([Figure 3A](#fig3){ref-type="fig"}), whereas for SBV both bivalent and bispecific complexes were capable of neutralization ([Figure 3B](#fig3){ref-type="fig"}). Interestingly, the length of the scaffolds did not have a major effect on neutralization efficiency of the RVFV VHH complexes, whereas the length did influence efficacy of the SBV complexes. Complexes based on the ELP3 scaffold (the longest tested) showed markedly higher neutralization efficiencies.

![RVFV and SBV-specific neutralization by monovalent VHHs and bacterial superglue-assembled VHH complexes.\
(**A**) RVFV- and (**B**) SBV-specific monovalent VHHs, VHH combinations and bivalent and bispecific ELP-based VHH complexes were tested in a RVFV or SBV-specific VNT assay. Complexes were formed by mixing the tagged versions of the VHHs with the indicated Catcher-containing ELP scaffolds of different lengths ([Figure 4](#fig4){ref-type="fig"}). Mixtures were subsequently pre-incubated with virus before adding them to susceptible cells. The ND~50~ values refer to total VHH per reaction as neutralization might be the result of cooperative action of VHH complexes and free VHHs. Averages of two biological replicate experiments are presented. Individual VHHs are color-coded based on the antigenic site they recognize as determined by competition ELISA ([Figure 2A and B](#fig2){ref-type="fig"}). Generally, most efficient neutralization was observed with multimerization of VHHs that each target a different antigenic site.](elife-52716-fig3){#fig3}

![Bacterial superglue-based VHH formatting.\
(**A**) SDS-PAGE of ELP-based scaffolds with an N-terminal SnoopCatcher and a C-terminal SpyCatcher domain. (**B**) SDS-PAGE of RVFV and (**C**) SBV-specific VHHs expressed with a C-terminal Snooptag or Spytag. The untagged variants were expressed with the llama antibody long hinge region. (**D**) Illustration of the bacterial superglue-based site-directed formation of a bispecific or bivalent VHH complex. (**E**) SDS-PAGE of the bacterial superglue-based formation of bivalent and bispecific VHH complexes using ELPs of various length. VHH RV115 and VHH RV150 were used as an example for VHH-A and VHH-B, respectively.](elife-52716-fig4){#fig4}

Prophylactic administration of ELP-based VHH complexes reduces morbidity and mortality in mice {#s2-6}
----------------------------------------------------------------------------------------------

Following the *in vitro* neutralization experiments, selected bivalent and bispecific complexes were evaluated in mouse infection experiments. To extend the *in vivo* half-life, the complexes were expressed with an albumin binding domain (ABD) ([Figure 5A,B,C](#fig5){ref-type="fig"}). Binding of a VHH complex to circulating albumin is expected to extend the half-life not only due to an increased size of the complex, but also as a result of recycling through the neonatal Fc receptor (FcRn) ([@bib50]; [@bib37]). Additionally, one trispecific RVFV VHH complex was constructed and evaluated to take the bacterial superglue approach to the next level and to make a construct targeting the red, blue and yellow antigenic sites within the RVFV-Gn~head~ domain simultaneously. To enable the construction of this trispecific complex we made use of a third bacterial superglue; SdyTag and SdyCatcher ([@bib62]). The specificity of all multimeric complexes to bind to RVFV-Gn~ecto~ or SBV-Gc~head~ was confirmed by indirect ELISA ([Figure 5D,E](#fig5){ref-type="fig"}) and efficient neutralization at nanomolar scale was confirmed by VNT ([Figure 5F](#fig5){ref-type="fig"}).

![Efficacy of RVFV and SBV-specific ELP-based VHH complexes in mice.\
(**A**) Illustration of ELP-based VHH complexes comprising an albumin binding domain (ABD). (**B**) SDS-PAGE of purified RVFV and SBV-specific ELP-VHH complexes. Uncoupled VHHs were removed by a Strep-tag based purification following the coupling. The asterisks (\*) indicate the glycosylated variants with higher molecular weights. (**C**) Species-specific albumin ELISA of the ABD containing ELP scaffold. Human, mouse or bovine albumin was coated at a 10 µg/ml concentration and the trispecific ELP scaffold containing an ABD domain (see **A**) was incubated in a dilution series. Binding was visualized with a Strep-Tactin-HRP conjugate. (**D**) Indirect RVFV-Gn~ecto~ and (**E**) SBV-Gc~head ~ELISA of purified RVFV and SBV-specific VHH complexes. (**F**) Neutralizing activity of the purified VHH complexes as determined by RVFV and SBV-specific VNTs. The ND~50~ values refer to the concentration of complexes. (**G**) Illustration of the RVFV and (**H**) SBV mouse models. (**I**) Survival curve of RVFV infected mice pre-treated with 150 µg of the RVFV-specific VHH complexes. (**J**) Survival curve of SBV-infected mice pre-treated with either 200 µg of SB10-ELP2~ABD~-SB10 or 100 µg SB10-ELP2~ABD~-SB9.](elife-52716-fig5){#fig5}

Mice were inoculated once with the complexes, followed by a lethal challenge dose of either RVFV or SBV. RVFV-specific complexes were evaluated in a BALB/c mouse model and SBV-specific complexes in IFNAR^-/-^ mice ([Figure 5G,H](#fig5){ref-type="fig"}; [@bib66]). The results of the RVFV mouse experiment showed that in the absence of the ABD domain (RV104-ELP2-RV107) morbidity and mortality could not be prevented or delayed, whereas treatment with both RV104-ELP2~ABD~-RV107 and RV104-ELP2~ABD~-RV150 resulted in a marked delay in mortality, of which the delay was most pronounced for RV104-ELP2~ABD~-RV107 ([Figure 5I](#fig5){ref-type="fig"}). Interestingly, the trispecific RV104-ELP-RV150-ELP~ABD~-RV107 complex protected the mice most efficiently, thereby suggesting that targeting of up to three antigenic sites simultaneously is very effective.

For SBV, the SB10-ELP2~ABD~-SB10 complex prevented mortality in 5 out of 6 mice whereas the SB9-ELP2~ABD~-SB10 complex protected all of the inoculated mice ([Figure 5J](#fig5){ref-type="fig"}). In both groups, none of the surviving animals showed any clinical signs of disease or significant weight loss. In addition, for all the antibody treated mice viral RNA loads in blood and tissue samples were markedly reduced in comparison to the control animals ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).

Formation and *in vivo* potency of bispecific llama-human chimeric antibodies {#s2-7}
-----------------------------------------------------------------------------

To improve the potency of the RVFV VHHs, we designed and constructed a llama-human chimeric bispecific format that encompass effector functions similar as conventional immunoglobulins. Moreover, we aimed to generate HCAbs that are suitable for therapeutic application in humans and with good manufacturability. We started with a human IgG~1~ CH2 and CH3 backbone, which enables binding to complement factor C1q and Fc receptors of immune cells triggering their activation. The interface between the CH2--CH3 domains also contains the binding site for the FcRn, responsible for the prolonged half-life of IgG, placental passage, and transport of IgG through mucosal surfaces ([@bib64]). Several bivalent and/or bispecific hIgG~1~Fc-VHH fusions were constructed ([Figure 6A,B](#fig6){ref-type="fig"}) and produced at small scale in HEK 293 T cells ([@bib43]). In line with the ELP results, efficient neutralization at ND~50~ \<1 nM was mainly observed with the bispecific constellations ([Figure 6C](#fig6){ref-type="fig"}) despite binding avidities to Gn~ecto~ that were highly similar ([Figure 6D](#fig6){ref-type="fig"}). The two most promising bispecific Fc fusions, 150-hIgG~1~Fc-104 and 107-hIgG~1~Fc-104 were subsequently produced at medium scale using a Chinese Hamster Ovary (CHO) cell-based transient expression platform (20 L) in disposable rocking bioreactors ([@bib10]). The purified material was subsequently tested in the RVFV BALB/c mouse model. In addition to prophylactic administration, therapeutic efficacy was also evaluated ([Figure 6E](#fig6){ref-type="fig"}). The results show that 60-100% protection was achieved with prophylactic administration and, remarkably, 60% protection was achieved after therapeutic administration ([Figure 6F,G](#fig6){ref-type="fig"}). Altogether, these results emphasize that VHH-based biotherapeutics hold great promise for the treatment of bunyavirus infections either prophylactically or therapeutically.

![Llama-human chimeric antibodies protect mice from lethal RVFV infection.\
(**A**) Illustration of the VHH and hIgG~1~Fc-based llama-human chimeric antibodies. (**B**) SDS-PAGE of the purified chimeric antibodies under non-reducing and reducing conditions. (**C**) Neutralizing activity of the purified chimeric antibodies expressed as ND~50~. (**D**) Indirect RVFV-Gn~ecto~-based ELISA of the chimeric antibodies. (**E**) Illustration of the mouse experiment setup. (**F**) Survival curve of RVFV-infected mice treated with 200 µg 150-hIgG~1~Fc-104. (**G**) Survival curve of RVFV-infected mice treated with 200 µg 107-hIgG~1~Fc-104. \* These chimeric antibodies were produced at medium scale in CHO cells.](elife-52716-fig6){#fig6}

Discussion {#s3}
==========

Bunyaviruses pose a clear and present danger to both animal and human health. The WHO recognized the threat for human health by including three bunyaviruses; RVFV, Crimean-Congo hemorrhagic fever virus (CCHFV) and severe fever with thrombocytopenia syndrome virus (SFTSV), on the Blueprint list of viruses likely to cause future epidemics and for which no countermeasures are currently available (<https://www.who.int/blueprint/priority-diseases/en/>). Although for some bunyaviruses veterinary vaccines are available or in development, for humans neither registered vaccines nor effective therapies exist.

The lack of knowledge about bunyavirus glycoprotein structures and immunogenic domains together with rudimentary knowledge on mechanisms of neutralization, have hampered the development of antibody-based bunyavirus therapies. However, novel structural data on the glycoproteins, obtained from combined X-ray and cryo-electron microscopy/tomography of whole virions for some members of the *Bunyavirales* provide now exciting new opportunities ([@bib72]; [@bib31]; [@bib24]; [@bib3]). For RVFV and SBV, a limited number of conventional mouse and rabbit mAbs as well as human antibodies have been described with neutralizing activity ([@bib72]; [@bib31]; [@bib6]; [@bib3]; [@bib65]; [@bib67]). With this study, i) we provide a whole panel of VHHs targeting RVFV or SBV, ii) show neutralizing activity of VHH-based complexes *in vitro* and *in vivo* and, iii) provide a broadly applicable method for the development of VHH-based biotherapeutics.

We specifically harnessed the advantageous characteristics of VHHs in combination with bacterial superglues to develop highly potent virus neutralizing complexes. A major advantage of the presented approach over more conventional approaches is the modularity and subsequent flexibility and directionality in complex construction, making selection of the most potent complexes a relatively easy task. This modularity additionally ensures efficient production, while genetic fusion of VHHs generally results in decreased production yields. Moreover, interference with CDRs is limited due to the flexibility in positioning of the superglue tags in the VHHs, particularly when compared to VHHs linked by genetic fusion, where N-terminal fusions can decrease affinity ([@bib16]). Multimeric complexes have not only proven effective in neutralizing viruses, but the presented bacterial superglue and module-based assembly strategy may also facilitate the development of biotherapeutics targeting cancer and toxins. Interestingly, a related approach primarily based on SpyTag-SpyCatcher interactions has recently shown promise to functionally inactivate the human epidermal growth factor receptor 3 (HER3) complex ([@bib1]). A potential disadvantage of using bacterial superglues in therapeutics is their intrinsic immunogenicity, leading to immune responses that do not contribute to protection and may even reduce efficacy, particularly with successive treatments. Nevertheless, the bacterial superglue strategy finds its added value, as we showed, as a very efficient intermediate step for identification of potent VHH combinations. After optimal combinations of VHHs are identified, these can be used to develop bispecific constructs with human IgG~1~ Fc domains.

One of the most profound observations we made in our study was the very strong synergistic effects in neutralization upon targeting of two or three different antigenic sites simultaneously. The synergistic effect of mixtures of antibodies targeting two or more distinct antigenic sites on RVFV virions was already reported more than 25 years ago by [@bib6]. They showed that conventional non-neutralizing RVFV monoclonal antibodies efficiently neutralized when they were used in combination ([@bib6]). The requirement to target more than one antigenic site for effective bunyavirus neutralization might be related to the broad range of receptor and attachment molecules used for viral attachment and entry in both insect and mammalian cells of which several are of non-proteinaceous nature ([@bib2]). Remarkably, we did not observe efficient neutralization by simply mixing VHHs targeting two distinct antigenic sites. Efficient neutralization required conjugation of the VHHs to a larger scaffold. Only these larger complexes were found to reduce or even prevent virus infection. Several mechanisms could explain the higher efficacy of multimeric complexes, including more efficient interference with receptor binding or interference with fusion through blocking viral glycoprotein conformational changes. Cross-linking of the glycoproteins may also reduce their overall degrees of freedom thereby preventing the glycoprotein shell to disassemble, which is a crucial step in the fusion process. Finally, binding of the complexes to multiple sites at the virion surface may facilitate complement activation and/or opsonization.

To gain insight into the mechanisms of RVFV neutralization, the VHHs were mapped on the Gn glycoprotein. This showed that all selected RVFV VHHs bind to the head domain of the Gn glycoprotein. In the virion context, Gn forms heterodimers with Gc and assembles into capsomers that are organized into an icosahedral lattice with a T = 12 quasisymmetry ([@bib24]; [@bib54]; [@bib33]). Gn is involved in receptor binding and Gc, as a class II fusion protein, is responsible for fusion of the viral membrane with the endosome ([@bib23]; [@bib39]). To prevent premature fusion of Gc, the Gc fusion peptide is shielded by Gn subdomain A (I) and the β-ribbon domain (II) ([@bib24]). Binding of VHHs that target the β-ribbon domain (blue panel) could potentially interfere with heterodimer dissociation for fusion or with fusion loop insertion. The VHHs targeting domain B (yellow panel) most likely interfere with receptor binding although specific functions have yet to be identified for this domain. Since the red VHH panel was unable to bind to any of the subdomains we expect these to bind at a domain interface.

The competition observed between the SBV-specific VHHs revealed that the majority (except for SB10) bind to one of three overlapping antigenic sites. X-ray crystallography studies previously showed that mAb 1C11 binds to the apical end of the Gc head domain ([@bib31]). Since SB11 and SB14 partially block antigen recognition by mAb 1C11, although not reciprocally, it appears that the antigenic sites recognized by the majority of our VHHs partially overlap with the antigenic site of mAb 1C11. The apical end of the Gc head domain thus appears to be highly immunogenic in llamas. A fourth, independent antigenic site is defined by SB10, for which an escape mutation at the hinge that connects the head domain to the stalk domain was identified. Intriguingly, the same point mutation was also found in an SBV field sample from a malformed goatling in 2012 (BH 233/12--1, GenBank: KC108871, [@bib17]). The virus in this goatling possibly replicated in the face of sub-neutralizing levels of antibodies that selected for this mutation. The mutation could affect the binding of the antibodies directly or the mutation could alter the conformation of Gc, leading to less efficient neutralization by SB10 or similar antibodies. We postulate that antibodies similar to SB10 are produced by more than just one natural target species, and that these antibodies pose a significant fitness cost for viral growth. As the biological role of the SBV Gc head domain is not yet fully understood, mechanisms for antibody protection remain speculative at this point. It becomes however apparent that binding of different antibodies to the SBV Gc head domain may alter the tertiary or quaternary structure of the spike and influence its structural dynamics: whereas at least two antigenic sites have been mapped to the putative trimerization interface of the head domain, SB10 binding likely restrains the head domain's mobility at its connection to the stalk. Together with inhibition of host cell attachment, these mechanisms may well contribute to virus neutralization.

Following the proof of principle experiments with the ELP-based complexes, selected VHHs were reformatted to bispecific hIgG~1~Fc-VHH fusion proteins ([@bib43]). In contrast to the ELP-based VHH complexes, the hIgG~1~Fc bispecific format is potentially capable of eliciting effector function and expected to have a prolonged half-life in plasma due to FcRn binding. Orthologous mouse and human FcγRs share \~60--70% identity, suggesting some incompatibility. However, a recent study shows that hIgG~1~ binds all mouse FcγRs with affinities that are similar to binding affinities of mouse IgG~2a~ to the mouse receptors ([@bib13]). Hence, FcγR-mediated effector functions of the hIgG~1~Fc based bispecifics are expected to be maintained in mice. Production of the two hIgG1Fc-VHH fusion proteins with the CHO cell based transient expression platform ([@bib10]) was efficient and preliminary data suggest that the expression and purification profiles are similar to what is usually seen with conventional bispecific antibodies. Nevertheless, a more comprehensive characterization of the molecules is still required to fully assess the manufacturability of this new bispecific format.

Altogether, our study describes a novel method to rapidly screen and format VHHs into highly potent multispecific complexes, which besides providing ammunition in the battle against (bunya)viruses, is expected to provide novel opportunities for the development of cancer and toxin biotherapeutics.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                       Designation                                         Source or\                       Identifiers                   Additional\
  (species) or\                                                                                           reference                                                      information
  resource                                                                                                                                                               
  --------------------------------------------------- --------------------------------------------------- -------------------------------- ----------------------------- ---------------------------------------------
  Strain, strain background (virus, *Ovis aries*)     RVFV-35/74                                          ([@bib41])                       RVFV-35/74                    Recombinant virus

  Strain, strain background (virus, *Homo sapiens*)   RVFV-Clone 13                                       ([@bib51])                       RVFV-Clone 13                 Natural isolate lacking 69% of the NSs gene

  Strain, strain background (virus, *Bos taurus*)     SBV NL-F6                                           ([@bib59]; [@bib34])             SBV NL-F6                     Natural isolate

  Strain, strain background (virus, *Ovis aries*)     SBV BH619                                           ([@bib68])                       SBV BH619                     Natural isolate

  Strain, strain background (*E. coli*)               TG1 cells                                           Immunosource                     60502--2                      Electrocompetent cells

  Strain, strain background (*E. coli*)               BL21 (DE3)                                          New England Biolabs              C2527H                        Competent cells

  Strain, strain background (*Mus musculus*)          BALB/cAnNCrl mice                                   Charles River Laboratories       BALB/cAnNCrl                  

  Strain, strain background (*Mus musculus*)          IFNAR-/-mice C57BL/6                                FLI                              B6.129S2-Ifnar1tm1Agt/Mmjax   

  Strain, strain background (yeast)                   *S. cerevisiae*                                     ([@bib29])                       *S. cerevisiae*               

  Cell line *Chlorocebus aethiops*                    Vero E6                                             ATCC                             CRL-1586                      

  Cell line *Spodoptera frugiperda*                   Sf9-ET cells                                        ATCC                             CRL-3357                      

  Cell line *Trichoplusia ni*                         High Five cells                                     Thermo Fisher Scientific         B855-02                       

  Recombinant DNA reagent                             pRL144                                              ([@bib26])                       pRL144                        Phage display vector

  Peptide, recombinant protein                        RVFV-Gn~ecto~                                       ([@bib11])                                                     

  Peptide, recombinant protein                        SBV-Gc~head~                                        ([@bib69])                                                     

  Recombinant DNA reagent                             Coding regions RVFV-Gn-ecto                         This paper                       Genscript                     [Table 1](#table1){ref-type="table"}

  Recombinant DNA reagent                             Coding region SBV-Gc-head                           This paper                       Genscript                     [Table 1](#table1){ref-type="table"}

  Recombinant DNA reagent                             pRL188                                              ([@bib27])                       AJ811567                      Yeast expression vector

  Recombinant DNA reagent                             pQE-80L                                             Qiagen                                                         Expression plasmid

  Recombinant DNA reagent                             pBAC3                                               Merck                            70088                         Baculo transfer plasmid

  Commercial assay, kit                               ELISA Streptactin coated microplates                IBA Lifesciences                 2-1501-001                    

  Commercial assay, kit                               FlashBac ULTRA system                               Oxford Expression Technologies   100300                        

  Commercial assay, kit                               Lightning-Link HRP Conjugation Kit                  Innova Biosciences               AB102890                      

  Other                                               Gravity Flow Strep-tactin Sepharose column          IBA                              2-1202-001                    

  Other                                               Amicon Ultra centrifugal filters                    Merck Millipore                  UFC900324                     

  Other                                               RVFV VLPs                                           ([@bib11])                                                     Virus-like particles

  Other                                               Ni-NTA resin                                        Qiagen                           30210                         

  Other                                               Protein A agarose Fast Flow 50%                     Sigma                            P3476                         

  Other                                               CHO transient expression system                     ([@bib10])                                                     Expression system

  Other                                               Human albumin                                       Sigma                            A9511                         

  Other                                               Mouse albumin                                       Sigma                            A3139                         

  Other                                               Bovine albumin                                      Sigma                            A7906                         

  Other                                               Bis-Tris NuPAGE Novex Gels                          Life Technologies                4--12% NP0322\                
                                                                                                                                           12% NP0342                    

  Other                                               TMB One Component HRP Microwell Substrate           SurModics                        TMBW-1000--01                 

  Other                                               HRP-conjugated Strep-Tactin                         IBA                              2-1502-001                    1:5000

  Commercial assay, kit                               QIAamp Viral RNA kit                                Qiagen                           52904                         

  Commercial assay, kit                               RNA Clean and Concentrator −5 kit                   Zymo                             R1013                         

  Commercial assay, kit                               Phusion Flash High-Fidelity PCR Master Mix          Thermo Fisher Scientific         F548                          

  Commercial assay, kit                               MagAttract Virus mini M48 kit                       Qiagen                           955336                        

  Commercial assay, kit                               DNA Clean and Concentrator-5 kit                    Zymo                             D4014                         

  Commercial assay, kit                               Superscript III First-Strand Synthesis System       Invitrogen                       18080051                      

  Sequence-based reagent                              JR565                                               This paper                       PCR primers                   GACAATTGATGACACATATAGCTT

  Sequence-based reagent                              JR829                                               This paper                       PCR primers                   ACAGAGCCTCTGAGAAATGTCTG

  Sequence-based reagent                              JR830                                               This paper                       PCR primers                   GATTTGCATACCAGTATTGGTG

  Antibody                                            Polyclonal HRP-conjugated goat anti-llama IgG-H+L   Bethyl                           A160-100P                     IPMA (1:1000), ELISA (1:2000)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Amino acid sequences of used domains and tags.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Protein                Amino acid sequence
  ---------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SBV Gc~head~           INCKNIQSTQLTIEHLSKCMAFYQNKTSSPVVINEIISDASVDEQELIKSLNLNCNVIDRFISESSVIETQVYYEYIKSQLCPLQVHDIFTINSASNIQWKALARSFTLGVCNTNPHKHICRCLESMQMCTSTKTDHAREMSIYYDGHPDRFEHDMKIILNIMRYIVPGLGRVLLDQIKQTKDYQALRHIQGKLSPKSQSNLQLKGFLEFVDFILGANVTIEKTPQTLTTLSLI

  Twin Strep-tag         GSAWSHPQFEKGGGSGGGSGGSAWSHPQFEK

  Yeast signal peptide   MMLLQAFLFLLAGFAAKISA

  SpyTag                 AHIVMVDAYKPTK

  SpyCatcher             DIPTTENLYFQGAMVDTLSGLSSEQGQSGDMTIEEDSATHIKFSKRDEDGKELAGATMELRDSSGKTIS\
                         TWISDGQVKDFYLYPGKYTFVETAAPDGYEVATAITFTVNEQGQVTVNGKATKGDAHIDGPQGIWGQLEWKK

  SnoopTag               KLGDIEFIKVNK

  SnoopCatcher           SSGLVPRGSHMKPLRGAVFSLQKQHPDYPDIYGAIDQNGTYQNVRTGEDGKLTFKNLSDGKYR\
                         LFENSEPAGYKPVQNKPIVAFQIVNGEVRDVTSIVPQDIPATYEFTNGKHYITNEPIPPKGPQGIWGQLDGHGVG

  ELP (1-2-3)            NL(GVPGVGVPGVGVPGEGVPGVGVPGVGVPGVGVPGVGVPGEGVPGVGVPGVGVPGVGVPGVGVPGEGVPGVGVPGVGVPG)~1-3~GLL

  HisTag                 MKGSSHHHHHH

  SdyCatcher             SSGLVPRGSHMASMTGGQQMGRGSSGLSGETGQSGNTTIEEDSTTHVKFSKRDANGKELAGAMIELRNLSGQTIQSWISDGTVKVFYLMPGTYQFVETAAPEGYELAAPITFTIDEKGQIWVDS

  SdyTag                 DPIVMIDNDKPIT

  RVFV-Gn-A              EDPHLRNRPGKGHNYIDGMTQEDATCKPVTYAGACSSFDVLLEKGKFPLFQSYAHHRTLLEAVHDTIIAKADPPSCDLQSAHGNPCMKEKLVMKTHCPNDYQSAHYLNNDGKMASVKCPPKYELTEDCNFCRQMTGASLKKGSYPLQ

  RVFV-Gn-ß              QDLFCQSSEDDGSKLKTKMKGVCEVGVQALKKCDGQLSTAHEVVPFAVFKNSKKVYLDKLDLKTEENGSGSGVVQIQVSGVWKKPLCVGYERVVVKRELSA

  RVFV-Gn-B              NLLPDSFVCFEHKGQYKGTMDSGQTKRELKSFDISQCPKIGGHGSKKCTGDAAFCSAYECTAQYANAYCSHANGSG
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Viruses, cells and media {#s4-1}
------------------------

Culture media and supplements were obtained from Gibco (Life Technologies, Paisley, United Kingdom) unless indicated otherwise. Virus stocks of RVFV strain Clone 13 ([@bib51]) and SBV strain NL-F6 ([@bib59]) were obtained after infections at low multiplicity of infection (0.01) of Vero E6 cells (ATCC CRL-1586, Teddington, United Kingdom). Vero cells were maintained in Eagle\'s minimal essential medium (EMEM) supplemented with 1% nonessential amino acids (NEAA), 1% antibiotic/antimycotic (a/a) and 5% foetal bovine serum (FBS), at 37°C with 5% CO~2~. Cells were regularly tested and were mycoplasma free.

Llama immunization and phage display selection {#s4-2}
----------------------------------------------

Two adult llamas (*Lama glama*, \#9342, \#9343) were intramuscularly (hind leg) immunized with 1 ml of RVFV strain Clone 13 (10^7^ TCID~50~) and another two llamas (\#9340, \#9341) were inoculated via the same route with SBV NL-F6 (10^6^ TCID~50~). Four weeks post immunization the VHH repertoire of the individual animals was amplified by RT-PCR from peripheral blood lymphocytes and inserted into phage display vector pRL144, as earlier described ([@bib26]). Additionally, a library was taken along from a llama (\#3467) that was three times immunized with 20 µg RVFV VLPs ([@bib11]) using a four week interval between immunizations 1 and 2 and a three week interval between immunizations 2 and 3. A week post the second vaccination a blood sample was taken for library preparation. Of note, simultaneously with the RVFV VLP antigen, this llama was also immunized with influenza antigens for a different study ([@bib28]). Libraries consisting of at least 10^7^ unique clones were generated and phages were rescued ([@bib27]). Phage display selections were subsequently performed by consecutive rounds of biopanning using RVFV-Gn~ecto~ and SBV-Gc~head~ expressed with a N-terminal Twin-Strep-tag as a bait antigen coated to Strep-Tactin coated microplates (IBA Lifesciences, Göttingen, Germany). To assess the enrichment of phages displaying RVFV-Gn~ecto~- or SBV-Gc~head~-specific VHHs, parallel phage ELISA and phage display selection were performed. After panning round two or three, individual clones were picked and grown in suspension for small-scale VHH production.

Isolation and identification of RVFV and SBV-specific VHHs {#s4-3}
----------------------------------------------------------

After the second or third round of panning and transduction to *E. coli* TG1 cells, individual colonies were picked and the VHH expression was induced with 3 mM IPTG. Soluble VHHs, extracted from the periplasm, were tested for binding to the RVFV-Gn~ecto~ and SBV-Gc~head~ antigens at 10-fold dilution as described below (ELISA). Individual VHHs were sequenced and aligned according to the IMGT system as described ([@bib25]; [@bib45]).

Production of RVFV-Gn~ecto~ and SBV-Gc~head~ antigen {#s4-4}
----------------------------------------------------

The coding regions of the RVFV-Gn~ecto~ (and smaller subdomains) and the SBV-Gc~head~ domain ([Table 1](#table1){ref-type="table"}) were gene synthesized by GenScript (Piscataway, New Jersey), and cloned into the pBAC3 baculo transfer plasmid (Merck) resulting in the following open reading frame (ORF) organization: signal sequence GP 64 -- SpyCatcher -- 10 GlySer linker -- *domain of interest* -- enterokinase - Twin Strep-tag. After rescue of the recombinant baculoviruses using the FlashBAC ULTRA system (Oxford Expression Technologies, Oxford, United Kingdom) in Sf9-ET cells (ATCC CRL-3357) according to the manufacturer's instructions, protein productions were initiated in High Five cells (Thermo Fisher Scientific, Landsmeer, The Netherlands) according to the manufacturer's instructions. The proteins of interest were subsequently purified from the culture supernatant using gravity flow Strep-tactin sepharose columns (IBA) according to the manufacturer's instructions. Finally, proteins were buffer exchanged to TBS with 200 mM NaCl using Amicon Ultra centrifugal filters (Merck Millipore, Burlington, Massachusetts).

VHH production {#s4-5}
--------------

For medium scale production of VHHs a yeast (*S. cerevisiae*) expression system was used. VHH gene fragments were either transferred from pRL144 or synthesized by GenScript and transferred into the yeast expression vector pRL188 ([@bib27]). The SpyTagged, SdyTagged and SnoopTagged versions of the VHHs were organized as follows: yeast signal sequence -- VHH -- 15 GlySer linker -- Spy/Sdy/SnoopTag -- GAA linker -- HisTag ([Table 1](#table1){ref-type="table"}). *S. cerevisiae* cells were induced for VHH expression using galactose and VHHs were purified from the culture supernatant by IMAC using Ni-NTA resin as described ([@bib27]). The buffer was exchanged to PBS using 3 kDa Amicon Ultra centrifugal filters (Merck Millipore).

ELP scaffolds {#s4-6}
-------------

Scaffold sequences of three different lengths ([Table 1](#table1){ref-type="table"}), based on previous work of Howarth and colleagues ([@bib73]; [@bib63]; [@bib46]), were codon-optimized for expression in *E. coli* and synthesized by GenScript. The gene fragments were cloned into the pQE-80L expression plasmid (ORF organization: HisTag -- SnoopCatcher -- ELP(1/2/3) -- SpyCatcher -- GlySer linker- ABD -- Entero kinase- Twin Strep-tag) (Qiagen, Hilden, Germany). For the expression of the scaffold that facilitated formation of a trispecific VHH complex the ORF organization was as follows: HisTag -- SnoopCatcher -- ELP -- SpyCatcher -- ELP - SdyCatcher -- GlySer linker- ABD -- Entero kinase -- Twin Strep-tag. Plasmids were subsequently introduced into *E. coli* BL21 competent cells by standard procedures. Transformed colonies were grown in Luria-Bertani (LB) broth and induced by IPTG using standard procedures. Cells were subsequently lysed under denaturing conditions, using 6 M guanidine hydrochloride as a denaturant. The scaffolds were purified from the supernatants by IMAC using Ni-NTA resin. Finally, the scaffolds were refolded by buffer exchange to PBS using 30 kDa Amicon Ultra centrifugal filters (Millipore).

Formation and purification of VHH complexes {#s4-7}
-------------------------------------------

Bivalent, bispecific and trispecific complexes were formed upon mixing of SpyTagged, SnoopTagged and/or SdyTagged VHHs with ELP scaffolds with C-terminally, N-terminally and/or internal Spy-, Snoop- or SdyCatchers. Briefly, scaffold and VHH solutions were diluted in PBS to concentrations between 5--32 µM. Subsequently, solutions were mixed at a 1:3-1:4 molar ratio (scaffold:VHH) under agitation (300 rpm) in a thermoblock (Eppendorf, Hamburg, Germany) for 3 hr at 20°C. Of note, for the trispecific complex the SdyTagged VHHs were incubated 3 hr at 20°C before the Spy- and SnoopTagged VHHs were added. When required, complexes were separated from uncoupled VHHs by Strep-Tactin based affinity chromatography according the manufacturer's instructions (IBA).

Construction and small-scale production of hIgG~1~Fc-VHH chimeric antibodies {#s4-8}
----------------------------------------------------------------------------

Tetravalency and/or bi-specificity was achieved by cloning one VHH in frame with the human IgG~1~ hinge, CH2 and CH3 exons ([@bib43]). The stop codon was removed to allow translation into the other VHH domain via a flexible synthetic linker (ERKPPVEPPPPP). The secreted antibody is a dimer of ∼110 kDa ([Figure 6B](#fig6){ref-type="fig"}). For a small scale production we stably transfected HEK 293 T cells with the resulting plasmid (pCAG hygro G1 variant) and purified bispecific antibodies from the supernatant using protein A affinity resin as described previously for HCAbs ([@bib15]).

Production of hIgG~1~Fc-VHH chimeric antibodies in CHO transient expression system {#s4-9}
----------------------------------------------------------------------------------

For medium scale production, the hIgG~1~Fc-VHH chimeric antibodies were expressed in a CHO transient expression system as previously described ([@bib10]). The sequences for the hIgG~1~Fc-VHH chimeric antibodies were synthesized by GeneArt, ThermoFisher and cloned into OriP-containing expression vectors ([@bib18]). Twenty litre cell culture volumes in disposable rocking bioreactors were subsequently transiently transfected with the expression vectors. The clarified harvest supernatant was purified using Protein A-based chromatography ([@bib47]).

SDS-PAGE {#s4-10}
--------

Samples were denatured using SDS-PAGE sample buffer with or without DTT and heated for 7--10 min at 95°C. Generally, samples containing 2.5--3 µg of total protein were loaded onto 4--12% or 12% Bis-Tris NuPAGENovex Gels (Life Technologies). Gels were stained with GelCode Blue Stain Reagent (Thermo Scientific, Waltham, Massachusetts) according to the manufacturer's instructions.

HRP conjugation of VHHs {#s4-11}
-----------------------

Purified VHHs were conjugated with HRP using the Lightning-Link HRP Conjugation Kit (Innova Biosciences, Cambridge, United Kingdom).

ELISAs {#s4-12}
------

Strep-Tactin microplates (Cat. No. 2-1501-001, IBA) were coated with 100 µl/well of RVFV-Gn~ecto~ or SBV-Gc~head~ at 1 µg/mL in ELISA binding buffer (25 mM Tris-HCl, 2 mM EDTA, 140 mM NaCl, pH 7.6) overnight at 4°C and then washed with PBS supplemented with 0.05% Tween 20 (PBST~20~) using an ELISA washer (6 pulses). Plates were blocked with 300 µl/well of ELISA blocking buffer (2% w/v skimmed milk in PBST~20~) for 1 hr at RT. Plates were subsequently incubated with 100 µl/well of five-fold dilution series in blocking buffer of unconjugated (indirect ELISA) VHHs, VHH complexes or VHH-hIgG~1~ fusions (starting at 10 µg/ml) for 1 hr at RT and then washed with the ELISA washer. HRP-conjugated goat anti-llama IgG-H+L (A160-100P, Bethyl, Montgomery, Texas) diluted 1:2000 in blocking buffer (100 µl/well) was used as a secondary antibody (1 hr at RT). For the competition ELISA, plates were loaded with 90 µl/well of the competing VHHs at 11.11 µg/ml in blocking buffer, followed by incubation for 1 hr at RT. Subsequently, 10 µl/well of the analyte HRP-conjugated VHHs (concentration differs per VHH and should reach E~450 ~0.5--0.8 in indirect ELISA) in blocking buffer were added, followed by incubation for 1 hr at RT. In all three ELISAs, TMB One Component HRP Microwell Substrate (TMBW-1000--01, SurModics, Minnesota) was added as a substrate. For the species-specific albumin ELISA of the ABD containing ELP scaffold, human (A9511 Sigma), mouse (A3139 Sigma) or bovine albumin (A7906 Sigma) was coated at a 10 µg/ml concentration. Plates were blocked with 300 µl/well of casein blocking buffer (2% casein in PBST~20~) for 1 hr at RT. Plates were subsequently incubated with 100 µl/well ABD containing ELP scaffold in a dilution series. Strep-Tactin-HRP conjugate (2-1502-001, IBA) diluted 1:5000 in casein blocking buffer (100 µl/well) was used as a secondary antibody (1 hr at RT).

Immunoperoxidase monolayer assay (IPMA) {#s4-13}
---------------------------------------

Cells were fixed with 4% v/v paraformaldehyde for 15 min at RT and then washed with PBST~20~. For cell permeabilization, the fixed cells were incubated with PBS supplemented with 1% v/v Triton X-100 for 5 min at RT. After three washes with PBST~20~, plates were subsequently blocked with IPMA blocking buffer (5% v/v horse serum in PBS) and incubated for 1 hr at 37°C. Diluted primary antibodies (VHHs) in blocking buffer (100 µL/well) were added. Plates were incubated for 1 hr at 37°C and then washed three times with PBST~20~. Subsequently, a HRP-conjugated goat anti-llama IgG H+L secondary antibody (Bethyl, A160-100P) in blocking buffer (1:1000, 100 µL/well) was added. Plates were incubated for 1 hr at 37°C and then washed three times with PBST~20~. For staining, 100 µL/well of a 0.2 mg/mL amino ethyl carbazole (AEC) solution in 500 mM acetate buffer (pH 5.0), 88 mM H~2~O~2~ was added as a substrate. Plates were incubated for 15--30 min at RT. Titers were calculated as the 50% tissue culture infective dose (TCID~50~)/mL using the Spearman-Kärber method.

SB10 escape mutant selection {#s4-14}
----------------------------

An escape mutant was selected after serial passaging of SBV NL-F6 under selective pressure by SB10. Initially, 1 ml of 10^4^ TCID~50~/ml virus suspension was incubated with 1 ml of SB10 solution at 10 µg/ml for 2 hr at RT. The virus-VHH mixture was then inoculated into T25 flasks seeded with 8 × 10^5^ Vero E6 cells, and subsequently incubated for 48--96 hr at 37°C with 5% CO~2~. Virus harvested from the culture supernatants and again subjected to SB10-mediated neutralization was used for sequential rounds of passaging. Suspected mutants from the sixth passage exhibiting cytopathic effects were selected for total RNA isolation using the QIAamp Viral RNA kit (Qiagen). Isolated RNA was purified and concentrated using the RNA Clean and Concentrator-5 kit (Zymo, Irvine, California) according to the instructions of the manufacturer. The SuperScript III First-Strand Synthesis System (Invitrogen) in combination with primer JR565 (GACAATTGATGACACATATAGCTT) was used to reverse transcribe the SBV Gc head domain RNA. An SBV Gc~head~-specific PCR product was amplified using the Phusion Flash High-Fidelity PCR Master Mix (Thermo Scientific) in combination with primer JR829 (ACAGAGCCTCTGAGAAATGTCTG) and JR830 (GATTTGCATACCAGTATTGGTG). PCR products were purified and concentrated using the DNA Clean and Concentrator-5 kit (Zymo). Finally, samples were sent to BaseClear (Leiden, The Netherlands) for Sanger sequencing. SBV NL-F6 without being passaged and SBV NL-F6 passaged without prior incubation with SB10 were used as controls.

Virus neutralization tests {#s4-15}
--------------------------

RVFV neutralization was assessed with the use of a highly sensitive VNT test as described ([@bib70]). SBV neutralization was assessed with the following method. In standard 96-well cell culture plates, 50 µl of two-fold dilutions of VHHs (starting at approximately 1000 nM) were incubated with 50 µl of a 10^4.2^ TCID~50~/ml SBV suspension for 2 hr at RT, before adding them to 1.5 × 10^4^ Vero E6 cells/well. VHH-SBV complexes and cells were incubated for 48 hr at 37°C with 5% CO~2~, and subsequently stained using IPMA. The neutralization capacity was calculated as ND~50~.

RVFV challenge experiments {#s4-16}
--------------------------

Six-week-old female BALB/cAnNCrl mice (Charles River Laboratories) were randomly divided into groups of 5 mice, kept in type III filter-top cages under BSL-3 conditions, and allowed to acclimatize for 6 days. The group size was computed (power 80%) with an estimated mortality (including euthanasia at HEP) in the non-treated control group of 95% and an estimated mortality in the treated group of 15--25% [http://clincalc.com/stats/samplesize.aspx](https://clincalc.com/stats/samplesize.aspx). Mice were prophylactically (t = −6 hr) or therapeutically (t = 18 hr) treated with purified VHH complexes (150 µg) or antibodies (150--200 µg) via the intraperitoneal route (in 100 µl PBS). Mice were challenged at t = 0 via intraperitoneal route with 10^3^ TCID~50~ of recombinant RVFV strain 35/74 ([@bib41]) in 100 µl medium. Challenged mice were closely monitored and humanely euthanized after reaching a humane endpoint.

SBV challenge experiments {#s4-17}
-------------------------

Eighteen male and female IFNAR-/-mice with a C57BL/6 genetic background (B6.129S2-Ifnar1tm1Agt/Mmjax) were obtained from the specific pathogen free breeding unit of the Friedrich-Loeffler-Institut. The animals were 4 to 6 weeks old and were randomly divided into 3 groups of 6 animals with equally distributed sexes. The group size calculation followed the same assumptions as for the RVFV challenge experiment. 24 hr prior to challenge infection, the mice were intraperitoneally treated with 200 µg (SB10-ELP2~ABD~-SB10) or 100 µg (SB10-ELP2~ABD~-SB9) of purified VHH complexes diluted in 100 µl PBS/mouse. Control animals received an equal volume of PBS. The mice were subcutaneously infected with SBV strain BH619 ([@bib68]) (10^5^ TCID~50~/mouse, diluted in 100 µl PBS). After challenge infection, the animals were closely monitored and weighed daily for 9 consecutive days. On days 3 and 7 post infection, EDTA blood samples were collected for RT-qPCR analyses. Animals showing severe clinical symptoms were immediately humanely euthanized. The remaining animals were euthanized after 21 days. At necropsy, serum and EDTA blood samples as well as tissue samples from liver and spleen were collected. RNA extraction was performed using a KingFisher 96 Flex (Thermo Scientific) and the MagAttract Virus Mini M48 Kit (Qiagen) according to the instructions of the manufacturer. For RT-qPCR analyses a previously described SBV-S-segment-specific assay was used in combination with the beta actin housekeeping gene as internal control ([@bib7]; [@bib56]). For quantification of viral RNA, an external SBV standard was included.

Statistical analyses {#s4-18}
--------------------

When appropriate, data was statistically analysed with GraphPad Prism version 8 software. Specific tests used are described in the figure legends.
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Decision letter

Kirkegaard

Karla

Reviewing Editor

Stanford University School of Medicine

United States

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Thank you for submitting your article \"Multimeric single-domain antibody complexes protect against bunyavirus infections\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by Karla Kirkegaard as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have shared their reviews with one another and the Editor has drafted this decision to help you prepare a revised submission.

Summary:

In this manuscript, the authors presented a strategy based on Llama-derived single-domain antibodies (VHHs) for the development of effective bunyavirus therapeutics. Rift Valley fever virus (RVFV) and Schmallenberg virus (SBV) were used as test cases. First, the authors isolated VHHs from a phage display library constructed from B cells of llamas immunized with RVFV vaccine and SBV VLP. While all animals showed virus-specific neutralizing antibody (NAb) titers, panning-derived VHHs showed low and moderate neutralization activities when tested individually and in a mixed form, respectively. Then, the authors utilized the SpyCatcher/SpyTag technology to create multimeric VHHs to test the synergistic effect in neutralization. Indeed, several multimeric VHHs showed greater potency than individual VHHs. Next, the authors created human IgG1Fc-VHH constructs for the best performers in the synergy test using these tethered or \"glued\" VHHs. CHO-expressed bispecific VHHs showed protection in a mouse challenge model of bunyavirus infection. Thus, this study presents

While none of the individual technical components in this strategy, e.g. llama VHH phage display and library screening, SpyCatcher/SpyTag for antibody coupling, and generation of bispecific antibodies using VHH and human Fc, is novel, their combination provides an elegant working strategy for developing VHH-based antibody therapeutics for an important viral pathogen. However, incorporation of these technical components into a working pipeline may justify some level of novelty.

Essential revisions:

1\) Please carefully review the claims and interpretations to ensure that they are justified and that alternative hypotheses are considered. For example, it is stated that: \"both the increased affinity due to multimerization as well as the increase in overall size of the VHH complex, resulting in additional steric hindrance, explain why the complexes outcompeted the mixtures of VHHs\" suggests that steric hindrance by SpyCatcher/Tag or human Fc is the mechanism of neutralization. Could there not be others?

2\) The SpyCatcher/tag and SnoopCatcher/Tag systems (bacterial SuperGlue) present powerful tools for protein engineering that are well-described here. There has been concern that these bacterial proteins would elicit a strong antibody response in humans. Here, the bacterial superglue to combine VHHs in an intermediate step before testing them in a bispecific form with a human Fc. It would be helpful to the community if you could discuss the design of this step, as opposed to the direct testing of VHH pairs in the hIgG1Fc form.

3\) The Figure legends, in general, are not sufficient. Readers will have to review Materials and methods to understand each, but still cannot understand completely without significant rewriting.

4\) The reviewers took special care to make detailed comments to improve the clarity of the presentation and the accuracy of the interpretations. Many of these are below. In general, please edit carefully to link each figure to the text describing it -- this is, of course, especially important in a paper with several groups and different kinds of approaches. One of the strengths of *eLife* is the opportunity to explain data carefully.

a\) Figure 1F, G should be combined into Figure 2, because the interpretation of Figure 1F and 1G are made as a part of Figure 2

b\) Subsection "Mapping of the SBV VHHs on the SBV-Gc~head~domain": Authors described that SB11 and SB14 target the same antigenic site as 1C11. However, the blocking with 1C11 still did not block the binding of SB11 or SB14 (Figure 2B), indicating that those VHH bind to antigenic sites different from that for 1C11.

c\) Subsection "Mapping of the SBV VHHs on the SBV-Gc~head~ domain" and Discussion paragraph six: Escape mutant for SB10 encoded the mutation of Y541C. It is not determined whether the mutation affects the binding of SB10, or the mutation alters the conformation of Gc, which leads to less efficient neutralization via SB10. Thus, the result does not provide conclusive evidence of binding region for SB10 and this conclusion should be softened.

d\) Figure 2E: Although figure legend or Materials and methods do not sufficiently describe the detail, the SB10 neutralizing antibody titer was lower with wt SBV than SBV-Y541C. This does not seem consistent with the description that SBV-Y541C is an escape mutant of SB10. Please explain.

e\) Figure 5C: The methods of albumin ELISA is not described.

f\) Figure 5---figure supplement 1: Statistical analysis should be provided for the comparison of viral RNA copies in Figure 5---figure supplement 1A and C.

g\) \"For SBV, the majority of our VHHs binds to one of three overlapping antigenic sites on the....\" Authors showed that blocking with two out of six VHH (SB11 and SB14) could partially block the binding of 1C11, but not vice versa. The description is thus not well supported by given results. Please rewrite for clarity and accuracy.
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Author response

> Essential revisions:
>
> 1\) Please carefully review the claims and interpretations to ensure that they are justified and that alternative hypotheses are considered. For example, it is stated that: \"both the increased affinity due to multimerization as well as the increase in overall size of the VHH complex, resulting in additional steric hindrance, explain why the complexes outcompeted the mixtures of VHHs\" suggests that steric hindrance by SpyCatcher/Tag or human Fc is the mechanism of neutralization. Could there not be others?

We acknowledge the point of the reviewer that besides interfering with receptor binding by steric hindrance other mechanisms could also explain why efficient neutralization is predominantly observed following multimerization of VHHs. One potential mechanism could involve a more efficient interference with glycoprotein conformational changes by VHH complexes compared to mixtures of VHHs. Bivalent/bispecific VHHs can potentially cross-link the glycoprotein shell at the virion surface, preventing pH-mediated glycoprotein conformational changes required for fusion of the viral and endosomal membranes. Additionally, at least in the in vivo situation, neutralization might be the indirect result of phagocytosis of opsonized virions either with or without a role for complement. In the revised version of the paper we elaborated on the potential mechanisms of neutralization in the Discussion section.

> 2\) The SpyCatcher/tag and SnoopCatcher/Tag systems (bacterial SuperGlue) present powerful tools for protein engineering that are well-described here. There has been concern that these bacterial proteins would elicit a strong antibody response in humans. Here, the bacterial superglue to combine VHHs in an intermediate step before testing them in a bispecific form with a human Fc. It would be helpful to the community if you could discuss the design of this step, as opposed to the direct testing of VHH pairs in the hIgG1Fc form.

We agree that potential anti-bacterial superglue immune responses are unfavourable and we indeed used the bacterial superglues primarily as an intermediate step before designing the bispecific human Fc-based molecules, thereby preventing the need to clone and express a large number of hIgG1Fc molecules. We have more clearly explained the rationale of our approach in the Discussion section.

> 3\) The Figure legends, in general, are not sufficient. Readers will have to review Materials and methods to understand each, but still cannot understand completely without significant rewriting.

We checked all figure legends and added information to facilitate interpretation of the figures without the need to review the Material and methods section.

> 4\) The reviewers took special care to make detailed comments to improve the clarity of the presentation and the accuracy of the interpretations. Many of these are below. In general, please edit carefully to link each figure to the text describing it -- this is, of course, especially important in a paper with several groups and different kinds of approaches. One of the strengths of eLife is the opportunity to explain data carefully.

This point is fully acknowledged and we carefully checked and improved when necessary the link between each figure and the corresponding text.

> a\) Figure 1F, G should be combined into Figure 2, because the interpretation of Figure 1F and 1G are made as a part of Figure 2

Although we understand the point being raised, combining Figure 1F, G with Figure 2 will result in a very large figure with reduced overall readability and interpretation. Moreover, Figure 1F and G are also closely linked to Figure 1C and D. To improve the overall interpretation of both figures and the link between them we added at the end of Figure legend 1 the following sentence: The colour coding of the individual VHHs is based on the outcome of the competition ELISA result as presented in Figure 2A and 2B.

> b\) Subsection "Mapping of the SBV VHHs on the SBV-Gc~head~ domain": Authors described that SB11 and SB14 target the same antigenic site as 1C11. However, the blocking with 1C11 still did not block the binding of SB11 or SB14 (Figure 2B), indicating that those VHH bind to antigenic sites different from that for 1C11.

We agree with the reviewer that the blocking pattern is not fully conclusive with regard to binding sites and that binding sites may only partly overlap or do not overlap at all. The non-reciprocal pattern could be explained by the different size of the antibody molecules and steric hindrance. VHHs may be able to "squeeze" between paratopes of 1C11 whereas the VHHs block efficiently binding sites for 1C11 (since its variable domains would need more space to bind), Secondly, the non-reciprocal pattern could also be the result of differences in avidity of the VHHs versus 1C11. Another, more complex explanation for the non-reciprocal blocking might be that SB11 and SB14 specifically bind to the trimer interface, thereby explaining why 1C11, which is known to bind upon trimer dissociation \[11\], is not able to bind in this situation. Blocking with 1C11, will subsequently prevent oligomerization of the spike but this will not prevent binding of SB11 and SB14 as part of the epitope is still accessible.

> c\) Subsection "Mapping of the SBV VHHs on the SBV-Gc~head~ domain" and Discussion paragraph six: Escape mutant for SB10 encoded the mutation of Y541C. It is not determined whether the mutation affects the binding of SB10, or the mutation alters the conformation of Gc, which leads to less efficient neutralization via SB10. Thus, the result does not provide conclusive evidence of binding region for SB10 and this conclusion should be softened.

We agree with the reviewer that the mutation could either directly affect the binding of SB10, or alternatively could indirectly influence neutralization by changing the overall Gc conformation. We added this alternative mechanism to the Discussion section and additionally added a question mark to the beige site in Figure 2G to highlight that the mapping is not fully conclusive.

> d\) Figure 2E: Although figure legend or Materials and methods do not sufficiently describe the detail, the SB10 neutralizing antibody titer was lower with wt SBV than SBV-Y541C. This does not seem consistent with the description that SBV-Y541C is an escape mutant of SB10. Please explain.

After checking Figure 2E we confirmed that the data was presented correctly. In the presence of low nM concentration of SB10 (20 nM), WT SBV is neutralized efficiently, whereas no neutralization was observed with the SBV-Y541C mutant in the presence of high concentrations of SB-10 (512 nM). Nevertheless, to improve the interpretation of the figure, without the need to carefully read the Y-axis title we reversed the axis numbers in line with the neutralization data presented in Figure 3.

> e\) Figure 5C: The methods of albumin ELISA is not described.

In the revised version of the manuscript additional details about the albumin ELISA are provided in the figure legend and the Material and methods section.

> f\) Figure 5---figure supplement 1: Statistical analysis should be provided for the comparison of viral RNA copies in Figure 5---figure supplement 1A and C.

In the revised version of the manuscript statistical analysis of Figure 5---figure supplement 1 is provided. Since animals were euthanized at different time points post infection, after reaching humane endpoints, a comparison between treated and non-treated animals could not be made in panel C.

> g\) \"For SBV, the majority of our VHHs binds to one of three overlapping antigenic sites on the....\" Authors showed that blocking with two out of six VHH (SB11 and SB14) could partially block the binding of 1C11, but not vice versa. The description is thus not well supported by given results. Please rewrite for clarity and accuracy.

We reformulated the statement and description to more accurately reflect the observations and validation of conclusions in the revised version of the manuscript.
